No photo of Anne E Laumann

View Scopus Profile

Anne E Laumann

  • 1052 Citations
1975 …2021
If you made any changes in Pure, your changes will be visible here soon.

Grants 2004 2021

Filter
Finished
Finished

Prot #8400-211: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 In Patients with Dermatomyositis

Laumann, A. E.

Parexel, Idera Pharmaceuticals, Inc.

3/14/16 → 3/14/19

Project: Research project

Prot #CC-220-SLE-001: A PILOT, PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Laumann, A. E.

PPD Development, Celgene Corporation

4/7/15 → 4/7/19

Project: Research project

Prot #X052171: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients with Pyoderma Gangrenosum

Laumann, A. E.

Therapeutics, Inc., XOMA (US) LLC

3/19/15 → 3/19/18

Project: Research project

Prot #X052172: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Laumann, A. E.

Clinipace, Inc., XOMA (US) LLC

3/19/15 → 3/19/18

Project: Research project

Efficacy of Ustekinumab (Anti-IL_12/23) followed by Abatcept (CTLA4-lg) for the tretment of Psoriasis Vulgaris

Laumann, A. E.

Benaroya Research Institute at Virginia Mason, National Institute of Allergy and Infectious Diseases

9/1/14 → 10/31/18

Project: Research project

Interleukin-23
Interleukin-12
Psoriasis
Recurrence
Ustekinumab

Prot #NOCOMPOUNDLUP0001: Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers

Laumann, A. E.

Janssen Research & Development, LLC

5/14/14 → 10/1/15

Project: Research project

Clinical and molecular Characterization of lichen Sclerosus as a Model of Vulvar Epithelial Fibrosis

Laumann, A. E. & Schlosser, B. J.

Dermatology Foundation

7/1/12 → 6/30/15

Project: Research project

Prot# CNTO1959PSO2001: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Gordon, K. B., Laumann, A. E. & West, D. P.

Parexel, Janssen Research & Development, LLC

5/4/12 → 5/4/15

Project: Research project

Prot#A6261008: A Randomized, Subject and Investigator-Blinded (Sponsor-Open), Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Multiple Doses of PD 0360324 in Subjects with Active Cutaneous Lupus E

Laumann, A. E.

Parexel, Pfizer Inc.

10/21/11 → 10/21/14

Project: Research project

Prot# CC-10004-PSOR-009: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis

Laumann, A. E. & Singri, P.

INC Research, LLC, Celgene Corporation

7/14/11 → 7/14/17

Project: Research project

Prot#R668-AD-0914: A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients with Moderate-to-Severe Extrinsic Atopic Dermatitis

Laumann, A. E., Paller, A. & West, D. P.

Ingenix Pharmaceutical Services, Inc., Regeneron Pharmaceuticals, Inc.

2/1/11 → 2/1/14

Project: Research project

Prot# CC-11050-CLE-002: A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects with Discoid Lupus Erythematosus and Subacut

Laumann, A. E. & West, D. P.

Celgene Corporation

12/8/10 → 12/8/13

Project: Research project

PROT# MEL-041509: Phase II Randomized, Double-Blind, Placebo-Controlled, Three-Arm,Dose-Finding, Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis

Laumann, A. E., Singri, P. & West, D. P.

OSI Pharmaceuticals, Inc.

10/7/09 → 10/7/12

Project: Research project

Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals with Severe Neurological Disorders

Laumann, A. E. & West, D. P.

Georgia Institute of Technology, National Institute of Biomedical Imaging and Bioengineering

9/30/09 → 8/31/12

Project: Research project

Prot# BAP01346: Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy

Dago, P. L., Laumann, A. E., Martini, M. C. & West, D. P.

Covance Periapproval Services, Inc., Basilea Pharmaceutica International Ltd.

5/26/09 → 5/26/12

Project: Research project

Prot# P10-023: A 10-Year, Post-Marketing, Observational, Registry of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)

Laumann, A. E. & West, D. P.

United BioSource LLC, Abbott Laboratories

4/20/09 → 8/31/19

Project: Research project

Tadalafil for the Treatment of Secondary Raynaud's Phenomenon

Laumann, A. E. & West, D. P.

Lilly ICOS LLC

5/19/08 → 5/19/11

Project: Research project

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis

Laumann, A. E. & West, D. P.

Bavarian Nordic A/S, National Institute of Allergy and Infectious Diseases

3/1/08 → 2/28/10

Project: Research project

Prot# C-2006-004-03: A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Exploratory Study of the Safety and Efficacy of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis that is Moderate in Severity

Laumann, A. E., Paller, A. & West, D. P.

Janssen Research & Development, LLC

4/2/07 → 4/2/08

Project: Research project

Prot: Evaluation of the Moisturizing Properties of a Hyaluronic Acid Based Oral Moisturizer Spray in ICU Intubated Patients

Laumann, A. E., West, D. P. & Wunderink, R. G.

Sage Products Inc.

2/16/07 → 2/16/08

Project: Research project

Prot# CTA018-CL-2001-1: A Randomized, Double-Blind, Parallel-Group, 4-Arm, 12 Week Study to Evaluate the Safety and Efficacy of Topically Applied CTA018 vs. Vehicle for the Treatment of Adult Subjects with Chronic Plaque Psoriasis

Laumann, A. E., Singri, P. & West, D. P.

Cytochroma Inc.

8/17/06 → 1/3/08

Project: Research project

Prot# SS-0601: TheraGauze Alone and Regranex® Gel 0.01% plus TheraGauze In the Treatment of Wagner Stage I Diabetic Foot Ulcers

Alam, M., Laumann, A. E. & West, D. P.

Soluble Systems, LLC

7/17/06 → 5/31/08

Project: Research project

Prot# 04-0-207: A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis

Laumann, A. E. & West, D. P.

Astellas Pharma US. Inc.

6/30/06 → 12/31/07

Project: Research project

Prot# ACD3101g: Raptiva® Epidemiologic Study of Psoriasis Outcomes and Safety Events (Response) in Patients with Chronic Moderate to Severe Plaque Psoriasis

Laumann, A. E., Singri, P. & West, D. P.

PPD Development, Genentech, Inc.

1/10/06 → 10/7/11

Project: Research project

Prot# 0432: A Multi-Center, Investigator-Blind, Bilateral Study to Determine the Efficacy and Safety of Mimyx Cream Applied Twice Daily in Reducing the Risk of Relapse in Atopic Dermatitis for 12 Weeks

Laumann, A. E., Paller, A. & West, D. P.

Stiefel Laboratories, Inc.

2/1/05 → 9/1/05

Project: Research project